Today's Healthcare Pulse
FDA greenlights durvalumab combo for high‑risk bladder cancer
The FDA approved durvalumab (Imfinzi) combined with Bacillus Calmette‑Guerin for BCG‑naïve, high‑risk non‑muscle invasive bladder cancer. The POTOMAC trial enrolled 1,018 patients and showed a 32% reduction in disease recurrence risk (hazard ratio 0.68, p=0.015). Durvalumab is given at 1,500 mg IV every four weeks for up to 13 cycles.
Also developing:
By the numbers: Apogee Therapeutics raises $1.3B royalty financing
Frailty-Related and Hepatic Prognostic Markers in Acute Biliary Tract Infections: A Diagnosis-Stratified Retrospective Cohort Study
A retrospective cohort of 94 adults with acute biliary tract infections revealed markedly higher 30‑day mortality in acute cholangitis (30%) versus acute cholecystitis (4.1%). Patients with cholangitis also showed lower prognostic nutritional index, higher FIB‑4 scores, reduced albumin and hemoglobin, and a greater prevalence of low CT‑derived psoas muscle area. Multivariable analysis identified the cholangitis diagnosis as the strongest predictor of mortality, while age and psoas area trended toward significance. The resulting model achieved an AUC of approximately 0.84, suggesting that frailty‑related imaging and laboratory markers can enhance early risk stratification.
Forecast-Driven Dynamic Physician Staffing in a Pediatric Emergency Department: A Prospective Quasi-Experimental Pilot Study
A prospective quasi‑experimental pilot at Hacettepe University Children’s Hospital tested forecast‑driven physician scheduling in its pediatric emergency department. Using the TiDE‑RIN deep‑learning demand model and linear programming, daily evening shift staffing was adjusted between three and six physicians. Compared with...
Correlates of Viral Load Suppression Among People Living with HIV on Antiretroviral Treatment in Mbujimayi, Democratic Republic of Congo: A...
A cross‑sectional study of 561 people living with HIV in Mbujimayi, Democratic Republic of Congo identified key behavioral determinants of viral load suppression. Strict antiretroviral therapy (ART) adherence increased suppression odds elevenfold, while having no casual sexual partners doubled the...
Association of Cervical Pessary Use with Preterm Birth in Singleton Pregnancies with a Short Cervix and Threatened Preterm Labor: A...
A retrospective cohort of 180 singleton pregnancies with threatened preterm labor and cervical length ≤25 mm compared cervical pessary use (2021‑2024) to historical controls (2017‑2020). Preterm birth before 37 weeks fell from 51.2 % to 20.9 % with pessary. Adjusted odds ratio 4.65...
Pulsed Intra-Arterial Infusion with Synchronously Controlled Blood Flow: A Novel Strategy for Optimizing Intra-Arterial Chemotherapy
Researchers introduced a pulsed intra‑arterial infusion technique with synchronized blood‑flow control (PBC‑IA) to improve chemotherapy delivery. In rabbit models, the method produced more than 20‑fold higher doxorubicin concentrations in the target gastrocnemius muscle compared with standard intravenous injection, while heart...
Medtech OEMs Face a Rare but Closing Window of Opportunity
Medtech original equipment manufacturers (OEMs) face a narrow window in 2026 to reshape their manufacturing portfolios as the CDMO market expands from $73 billion in 2022 to $91 billion in 2024. A recent $1.5 billion sale of a medical OEM division highlighted premium...
Finasteride for Male Baldness Is Rewriting the Rules of Male Beauty
Finasteride, a prescription pill originally approved for prostate health, has become the go‑to treatment for male pattern baldness, delivering a decade‑long slowdown of hair loss for most users. Clinical studies show that a majority of men on the drug experience...
The CY 2027 MA Rate Announcement as an Entrepreneur’s Prospectus
CMS released the CY 2027 Medicare Advantage and Part D rate announcement on April 6, 2026, confirming a 2.48% net average payment increase—about $13 billion more than 2026. Beyond the headline, the rule introduces several operational mandates: unlinked chart‑review diagnoses are excluded from...
Navigated TMS Significantly Boosts Combat PTSD Recovery Rates
A randomized clinical trial led by UT Health San Antonio demonstrated that MRI‑guided, robotic‑controlled navigated transcranial magnetic stimulation (TMS) added to intensive psychotherapy produced significant symptom relief for combat‑related PTSD. Eighty‑five percent of participants receiving active navigated TMS showed clinically...
Designing Secure & Scalable Healthcare Applications
Healthcare mobile applications are proliferating, but they must balance patient‑data security with the ability to handle surging usage. Developers face three core hurdles: strict HIPAA/GDPR compliance, fragmented interoperability, and the need for elastic performance under heavy loads. Cloud platforms, micro‑service...
Outdated Hospital Systems Invite Ransomware, Endanger Patient Care
I was just listening to an interview on the radio with a person who worked at a hospital. 1. Your cyber insurance makes you a target. They know how much you can pay. 2. Don’t use your backups until you...
DTC Affiliate Marketing Shifts to GLP‑1s Amid Pharma Proxy War
Look, I'd be lying if I said this was the first (or second or fiftieth) MEDVi article. But this is about more than MEDVi or even all the spam, grey zone marketing, and Succession-level drama of business partners acquired by...
A Seasoned Pediatrician on What the Latest Vaccine Victory Means for Kids
A federal judge issued a preliminary injunction in mid‑March that temporarily halted the CDC’s Advisory Committee on Immunization Practices (ACIP) from implementing controversial changes to the U.S. childhood vaccine schedule. The stay follows a lawsuit filed by the American Academy...
Gilead Buys Tubulis to Boost ADC Platform
Gilead Sciences announced a definitive agreement to acquire Germany‑based Tubulis for up to $5 billion, adding a clinical‑stage antibody‑drug conjugate (ADC) pipeline and a next‑generation linker‑payload platform. The deal brings Tubulis’ lead candidate TUB‑040, a NaPi2b‑targeting ADC in phase 1b/2 for platinum‑resistant...
Terns Rebuffed a Higher Bid Before Selling to Merck
Terns Pharmaceuticals accepted Merck & Co.'s $53‑per‑share, $6.7 billion buyout, a price roughly 15% below an earlier $61 offer from an unnamed Party C. Party C’s proposal included a contingent $9‑per‑share payout tied to FDA approval of TERN‑701, but it withdrew after updated...
How To Leverage AR Collection Services as an Elastic Workforce for Growing DME Businesses
Durable medical equipment (DME) providers face growing claim backlogs and cash‑flow strain as payer rules shift and order volumes fluctuate. To avoid overburdening internal teams, many are turning to accounts‑receivable (AR) collection services as an elastic workforce. These external partners...
Meta‑analysis and NIH Trial Link Ultra‑processed Foods to 32 Diseases and 500 Extra Calories Daily
A BMJ meta‑analysis tying ultra‑processed food (UPF) consumption to 32 health conditions and a NIH‑run randomized trial documenting a 508‑calorie daily surplus on a UPF diet together highlight the public‑health threat of processed foods and the lack of FDA labeling...
Semaglutide Improves Kidney, Survival Outcomes Along CKD Spectrum
Semaglutide (Ozempic) significantly lowered the risk of kidney failure and all‑cause mortality in the FLOW trial, which enrolled 3,533 type‑2 diabetes patients with chronic kidney disease. The drug reduced the primary composite kidney outcome by 24% (HR 0.76) and cut overall...
Neurocrine Biosciences to Acquire Soleno Therapeutics for $2.9 Billion in Cash
Neurocrine Biosciences announced a definitive agreement to purchase Soleno Therapeutics for $53 per share, a $2.9 billion cash deal that represents a 34% premium. The acquisition adds Vykat XR, the only FDA‑approved treatment for hyperphagia in Prader‑Willi syndrome, to Neurocrine’s rare‑disease portfolio....
Winning Peer-to-Peer Calls Requires Speaking the Payer’s Language
Physicians are not losing many peer-to-peer calls because they are clinically wrong. They are losing because they are arguing care in a process that is judging criteria. That is the most important insight in this KevinMD article. On one side of the call...
The Dark Side of Music as ‘Therapy’
The article highlights that while music is widely embraced as a low‑risk therapeutic tool in hospitals and care settings, it can also cause harm when imposed without consent. It cites historical examples of music as torture and recent evidence that...
Understanding Generation 2 Patient Engagement Platforms
The article distinguishes two generations of patient engagement platforms. First‑generation tools deliver information but flood staff inboxes, requiring manual responses and new staffing roles. Second‑generation solutions embed AI‑driven protocols that answer routine questions automatically, leaving clinicians only to handle escalations....
Telix Pharmaceuticals Posts 24% Revenue Rise, Shares Jump 5%
Telix Pharmaceuticals announced first‑quarter revenue of $230 million, up 24% year‑over‑year, and reaffirmed its full‑year 2026 guidance of $950‑$970 million. The earnings beat lifted the Nasdaq‑listed stock about 5% in trading, underscoring growing investor confidence in the company’s precision‑medicine platform.
Idaho Cut Services for People With Schizophrenia. Then the Deaths Began.
Idaho eliminated Medicaid‑funded assertive community treatment (ACT) services for people with severe mental illness, including schizophrenia, in late 2025. Within weeks, several patients lost access to home‑based care and medication management, and at least five deaths were reported, highlighting the...
The Vitamin Deficiency Linked To Alzheimer’s And Dementia
A longitudinal study of 1,685 older Americans tracked for about five years found that low vitamin D levels significantly increase the likelihood of developing dementia and Alzheimer’s disease. Participants with deficient vitamin D were 53% more likely to develop dementia and 69%...
VC Activity Drives March Med-Tech Financings to $2.4B
In March, the med‑tech sector highlighted three breakthrough programs that attracted venture capital attention. Jiangsu and Shanghai Hengrui patented selective Nav1.8 sodium‑channel blockers and plan IND‑enabling toxicology this year, targeting chronic pain with a Phase I start in 2027. New single‑cell...
Appointments and Advancements for April 7, 2026
On April 7, 2026, BioWorld reported three notable biotech developments. Jiangsu and Shanghai Hengrui patented novel Nav1.8 sodium‑channel blockers, a potential new class for chronic pain management. Researchers highlighted hematopoietic stem‑cell studies that implicate inflammation as an early driver of...
Regulatory Actions for April 7, 2026
On April 7, 2026 regulators issued several high‑profile decisions across biopharma and medical‑technology. Allevion secured FDA clearance for its next‑generation gene‑therapy platform, Regeneron obtained EMA approval for a monoclonal antibody targeting a rare autoimmune disorder, and Stereotaxis earned a CE...
Kennedy Sidestepping Court Order Sidelining ACIP?
BioWorld’s April 7 briefing highlights three notable developments: Jiangsu and Shanghai Hengrui have patented a new class of Nav1.8 sodium‑channel blockers aimed at chronic pain treatment; recent hematopoietic stem‑cell research underscores inflammation’s role in initiating leukemia; and Infinimmune presented preclinical data...
South Korea Streamlines Biosimilar Review, Clinical Trials
BioWorld Asia’s April 7 2026 briefing highlighted three emerging biotech developments. Jiangsu and Shanghai Hengrui patented selective Nav1.8 blockers that deliver strong analgesic effects with minimal off‑target activity, positioning them as potential first‑in‑class chronic pain therapies. New research linked chronic inflammation in...
Gilead Buying Tubulis and Its ADCs in $5B Takeover Bid
BioWorld’s April 7 briefing spotlights three notable biotech developments. Researchers at Jiangsu and Shanghai Hengrui have patented selective Nav1.8 sodium‑channel blockers that deliver strong analgesic effects with minimal off‑target activity, opening a potential new class for chronic pain. Parallel studies reveal...
Sononeu Wins $5.2M ARPA-H Grant for Ultrasound-Activated Therapeutics
Sononeu, a Boston‑based biotech, secured a $5.2 million grant from the U.S. Advanced Research Projects Agency for Health (ARPA‑H) to advance its ultrasound‑activated therapeutic platform. The award will fund pre‑clinical development of drug‑delivery systems that release payloads only when exposed to...
Amplia Halts Enrollment in Phase II Pancreatic Cancer Trial
Amplia Therapeutics announced it is halting enrollment in its phase II trial of the investigational pancreatic cancer agent after an interim safety review revealed concerning signals and modest efficacy. The study, which began enrolling patients in early 2025, was designed to...
Development of Emerging Modalities: Challenges and Strategies
The article outlines that emerging therapeutic modalities—such as antibody‑drug conjugates, multispecific antibodies, viral vectors, gene‑editing and RNA‑based medicines—present far greater molecular and manufacturing complexity than traditional biologics. Four primary hurdles are identified: structural heterogeneity, absence of universal platform processes, difficulty...
Other News to Note for April 7, 2026
Jiangsu and Shanghai Hengrui Pharmaceuticals have patented novel Nav1.8 sodium‑channel blockers that selectively target pain signaling, showing strong pre‑clinical analgesic activity with minimal off‑target effects. Parallel research highlights chronic inflammation’s role in reshaping hematopoietic stem cells, creating a microenvironment that...
In the Clinic for April 7, 2026
BioWorld’s April 7, 2026 clinic roundup compiles a broad set of data snapshots, special reports and infographics spanning biopharma, medical technology, and emerging therapeutic areas. The collection links to analyses on M&A activity, GLP‑1 developments in China, mRNA vaccine research, pulsed‑field ablation...
Best of BioWorld: Q1
Jiangsu and Shanghai Hengrui Pharmaceuticals have patented selective Nav1.8 sodium‑channel blockers that show potent analgesic activity with minimal off‑target effects, opening a new avenue for chronic pain treatment. Parallel research highlights how chronic inflammation reshapes hematopoietic stem cells, fostering early...
Financings for April 7, 2026
Jiangsu and Shanghai Hengrui have patented selective Nav1.8 sodium‑channel blockers that alleviate pain in rodent models without motor side effects, and plan IND‑enabling studies later this year. Parallel research highlights chronic inflammation’s role in reshaping hematopoietic stem cells, fostering leukemic...
Massachusetts Hospital Turning Ambulances Away After Cyberattack
A cyberattack on Signature Healthcare Brockton Hospital in Massachusetts forced the facility to turn away ambulances and activate downtime procedures, cancelling chemotherapy infusions while keeping emergency rooms and surgeries operational. The hospital is working with external experts to restore systems,...
H.I.G.-backed Vernacare Scoops up Eakin Surgical
Vernacare, backed by private equity firm H.I.G., announced the acquisition of Eakin Surgical, a UK manufacturer of single‑use surgical instruments and procedure solutions. The deal adds a proven line of disposable tools to Vernacare’s existing portfolio, strengthening its foothold in...
Medicare Advantage Left 3 Million Seniors without a Plan, and Options Are Shrinking
Medicare Advantage enrollment, once a growing staple, saw a sharp reversal in 2026 as nearly 3 million seniors were forced to leave their plans. Disenrollment rates surged to 10% of beneficiaries, driven by insurers exiting counties due to rising medical costs...
Gilead's $3.1B Deal Expands ADC Portfolio
Gilead continues M&A surge with $3.1B deal for ADC specialist Tubulis https://t.co/xEMXvDq2LL by @gwendolynawu $GILD #biotech
Re: Increase in Remote Overseas Primary Care Consultations
A growing number of UK‑trained GPs are delivering primary‑care consultations from overseas locations, often in low‑tax jurisdictions such as Dubai. This trend raises questions about which regulatory body has authority over remote diagnoses, prescriptions, and liability. Critics argue that doctors...
ARPA-H Selects Three Teams in $100M Effort to Repair and Regrow Ailing Joints
ARPA-H announced a $100 million program to fund clinical trials for joint regeneration. Three leading academic centers were selected to test innovative therapies aimed at repairing and regrowing damaged cartilage and bone. The projects will explore senolytic drugs, engineered tissue scaffolds,...
Transforming the Healthcare Supply Chain: The Real Challenges We’re Facing (1 of 3)
In this episode, host Dave Kreisler talks with AI strategist and cybersecurity veteran Sagar Panja about the rapid shift in AI adoption across businesses and the cultural, data, and security challenges that accompany it. Panja emphasizes that successful AI implementation...
Zimmer Hires Chief Science, Technology and Medical Affairs Officer
Zimmer Biomet announced the appointment of orthopedic surgeon Jonathan Vigdorchik as its chief science, technology and medical affairs officer, effective April 14. In his new role, Vigdorchik will oversee AI, robotics, smart implants, data analytics, and the company’s medical‑education strategy....
Is Apical Vertebral Translation Measure the New COBB Angle?
A recent study of 189 adult degenerative scoliosis (ADS) patients over age 50 found that the traditional Cobb angle does not predict severe hip osteoarthritis (OA). Instead, greater apical vertebral translation (AVT) and increased pelvic obliquity were strongly associated with...
Gilead Continues M&A Surge with $3.1B Deal for ADC Specialist Tubulis
Gilead Sciences announced a deal to acquire German biotech Tubulis for $3.15 billion upfront, potentially rising to $5 billion with milestones. The purchase adds a next‑generation antibody‑drug conjugate (ADC) platform and two clinical candidates, TUB‑040 and TUB‑030, to Gilead’s oncology pipeline. This...
Silent Cancers Demand Regular Screenings and Body Awareness
You don’t always feel cancer in the early stages. Some cancers stay silent until they’re advanced... Your real obligation: pay attention to persistent changes in your body and keep up with proven screenings like mammograms, Pap tests, and colonoscopies.
Terns Sold to Merck for 13% Lower than Pharma's Initial Offer because of Clinical Data
Merck agreed to acquire Terns Pharmaceuticals for $6.7 billion, a price roughly 13% lower than its initial offer after new clinical data raised concerns. The renegotiated deal reflects the impact of late‑stage trial results on valuation in the biotech M&A wave....